Drug Study

NAME OF DOSAGE/ MECHANISM INDICATIO CONTRAINDICATION ADVERSE EFFECT NURSING

DRUG FREQUENCY OF ACTION N RESPONSIBILITIES
Dexketoprof 50mg tab PO It is a non- Used to Not contraindicated No adverse Assessment:
en T.I.D p.c steroidal treat mild for the patient reaction noted  Verify the
anti- to patient’s
inflammatory moderate  Hypersensiti Significant: Renal diagnosis
drug (NSAID) pain vity to effects (e.g. and the
that reduces caused by dexketoprof deteriorated renal need for
prostaglandin patellar en, aspirin, function, fluid administerin
synthesis via dislocatio or other retention, oedema, g
inhibition of n NSAIDs. increased BUN or medication
cyclooxygena  History of creatinine), hepatic to confirm
se pathway bronchial effects (e.g. the
(both COX-1 asthma or significantly indication
and COX-2) asthma elevated AST/ALT), for
activity. attacks, increased risk of MI administerin
bronchospas or stroke (high g
m, doses), dexketoprof
angioneuroti exacerbated colitis en
c oedema, or Crohn’s disease,  Check for
urticaria, inhibited platelet current
acute rhinitis aggregation, medication
or nasal prolonged bleeding history
polyps that time, masked (Taking
were symptoms of corticosteroi
precipitated infection. ds,
or caused by Blood and anticoagulan
aspirin or lymphatic system t, antacids,
other disorders: Anaemia cholinergic
NSAIDs; . agonists
 active, Cardiac with
suspected, disorders: Palpitati Dexketoprof
or recurrent on. en may
peptic ulcer Eye increase risk
and disorders: Blurred for internal
gastrointesti vision. gastrointesti
nal Gastrointestinal nal upset or
haemorrhag disorders: Nausea, bleeding)
e, other vomiting,  Ask the
active diarrhoea, patient for
bleeding or abdominal pain, any medical
bleeding dyspepsia, dry or family
disorders, mouth, gastritis, history of
haemorrhagi constipation, hemophilia,
c diathesis flatulence, gastrointesti
and other haematemesis. nal ulcers or
coagulation General disorders bleeding
disorders and administration disorders,
 any history site for the
of conditions: Fatigue reason that
gastrointesti , asthenia, malaise, NSAIDs have
nal bleeding, pyrexia, inj site anti- platelet
ulceration, reactions (e.g. effects that
or pain, inflammation, can
perforation, haemorrhage, exacerbate
including bruising). bleeding
related to Musculoskeletal tendencies
previous and connective Interventions:
NSAIDs tissue  Administer
treatment; disorder: Rigor. dexketoprof
chronic Nervous system en after
 dyspepsia, disorders: Headach meals as
Crohn’s e, dizziness, aseptic prescribed
disease, meningitis, vertigo. to reduce
ulcerative Psychiatric occurrence
colitis, disorders: Insomni of stomach
severe heart a, anxiety, upset.
failure, somnolence.  Educate the
severe Reproductive patient
dehydration system and breast about the
(caused by disorders: Impaire action,
diarrhoea, d female fertility. indication,
vomiting, Skin and common
insufficient subcutaneous side effects
fluid intake), tissue and adverse
varicella disorders: Rash, reactions to
infection, pruritus, note when
history of dermatitis, taking
CABG increased Dexketoprof
 known sweating. en, to
phototoxic Vascular inform the
or disorders: Flushing, patient on
photoallergic hypotension. the basics of
reactions Potentially the
during Fatal: Gastrointesti medication.
therapy with nal bleeding,  Monitor I
ketoprofen ulceration, or and O,
or fibrates. perforation; NSAIDs may
 Moderate to asthma attacks or cause
severe renal bronchospasm. impaired
(CrCl ≤59 Rarely, Stevens- urinary
mL/min) Johnson syndrome, elimination
 impairment. exfoliative Evaluation:
 Severe dermatitis, toxic
hepatic epidermal  Monitor
(Child-Pugh necrolysis, patient’s
score 10-15) anaphylactic shock. response to
impairment. the
 Pregnancy medication
(3rd to check if
trimester) the
and medication
lactation. is effective
or need to
be adjusted
 Ask the
patient to
repeat
information
about the
medication
to evaluate
effectivenes
s of health
teaching
 Check for
any signs of
gastrointesti
nal bleeding
and
discontinue
if there is
any
evidence of
such.
DIAGNOSTIC AND LABORATORY EXAMINATION

TEST DATE PATIENT RESULT REFERENCE INTERPRETATION ANALYSIS

RANGE
CBC 8/01/22 WBC: 9.91 4.5- 11.0 Normal
Neutrophils: 65 35-65 Normal
Lymphocytes: 28 20- 40 Normal
Monocytes: 6 2-6 Normal
Eosinophils: 1 0-5 Normal
Basophils: 0 0- 1 Normal
RBC: 5.58 4.5-6.0 Normal
HGB: 117 120-160 Decreased
HCT: 0.376 0.37-0.47 Normal
MCV: 67.4 81-99 Decreased
MCH: 21.0 27-31 Decreased
MCHC: 311 310-360 Normal
RDW: 15.9 11.5-14.5 Normal
Platelet Count: 276 150-450 Normal
MPV: 8.7

TEST DATE PATIENT RESULT REFERENCE INTERPRETATION ANALYSIS

RANGE
Sodium, Potassium 8/01/22 Serum Sodium: 136- 145 Normal
130.7
Serum Potassium: 3.5-5.1 Normal
3.68

TEST DATE PATIENT RESULT REFERENCE INTERPRETATION ANALYSIS

RANGE
Urinalysis 8/01/22 Physical examination:
 Color: Yellow
Transparency: Cloudy
Chemical Examination:
Reaction: 7.0
Specific Gravity: 1.025
Sugar: Negative
Protein: Negative
Ketones: Negative
Blood: Negative
Bilirubin: Negative
Urobilinogen: Normal
Leukocytes: Negative
Nitrite: Negative
Microscopic
Examination:
Squamous Epithelial
cells: Few
Non- Squamous
epithelial Cells: None
Mucus Threads: Few
RBC: 0-1
WBC/Pus: 0-1
Bacteria: Few
Dysmorphic RBC: None
Crystals: None
Casts: Amorphous
Phosphates (Moderate)
Yeast Cell: None

TYPE DATE FINDINGS IMPRESSION

Chest x-ray, AP/L view 8/01/22 Lung field is clear, No active or Normal chest findings
chronic infiltrates
Heart is not enlarged
Mediastinum is not widened
Sulci and diaphragm are intact
Bones and soft tissues are
unremarkable